Global Oral Mucositis (OM) Market Insights, Epidemiology and Market Forecast to 2027: Focus on United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China
DUBLIN, Oct. 31, 2018 /PRNewswire/ --
The "Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of OM in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Oral Mucositis (OM) from 2016 to 2027 segmented by G8 Countries market. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Oral Mucositis (OM) - Disease Understanding and Treatment Algorithm
The Oral Mucositis (OM) market report gives the thorough understanding of the Oral Mucositis by including details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Oral Mucositis in the US, Europe, Japan, and China.
Oral Mucositis Epidemiology
The Oral Mucositis (OM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for G8 countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Diagnosed Incident cases, Grade-specific cases, Risk Factor Associated cases), scenario of Oral Mucositis (OM) in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) Japan and China from 2016-2027.
According to this research, total diagnosed incident population of Oral Mucositis (OM) in G8 countries markets was found to be 5,333,193 in 2016.
Oral Mucisitis Drug Chapters
This segment of the Oral Mucositis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic market of G8 Countries is driven majorly by Kepivance, Magic mouthwash, approved mouth rinse (Episil (SP-03), Gelx, Neutrasal, ProThelial, Mucotrol and Painkillers. Detailed chapter for upcoming therapies like EC-18 (Enzychem Lifesciences Corporation), SGX942 (Soligenix Inc.), OPC-12759 (Otsuka Pharmaceuticals), RRx-001 (EpicentRx), AG013 (Oragenics, Inc.), Validive (Monopar Therapeutics), GC4419 (Galera Therapeutics), SAMITAL (Indena S.p.A), Brilacidin (Innovation Pharmaceuticals), Mucomel (Spherium Biomed) and Folotyn and Leucovorin have been covered in the report.
Oral Mucositis Market Outlook
The Oral Mucositis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of Oral Mucositis in G8 countries was found to be USD 638.8 Million in 2016, and is expected to increase from 2016-2027.
Oral Mucositis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Oral Mucositis Report Insights
-- Patient Population
-- Therapeutic Approaches
-- Pipeline Analysis
-- Market Size and Trends
-- Market Opportunities
-- Impact of upcoming Therapies
Oral Mucositis Report Key Strengths
-- 10 Year Forecast
-- G8 Countries Coverage
-- Epidemiology Segmentation
-- Drugs Uptake
-- Highly Analyzed Market
-- Key Cross Competition
Oral Mucositis Report Assessment
-- Current Treatment Practices
-- Unmet Needs
-- Detailed Pipeline Product Profiles
-- Market Attractiveness
-- Market Drivers and Barriers
Key Benefits
-- This report will help to develop Business Strategies by understanding
the trends shaping and driving Oral Mucositis market
-- Organize sales and marketing efforts by identifying the best
opportunities for Oral Mucositis market
-- To understand the future market competition in the Oral Mucositis
market.
Companies Mentioned
-- Helsinn Healthcare
-- EUSA Pharma/Canbridge Life Sciences
-- Solasia Pharma / Camurus AB
-- Access Pharmaceuticals
-- Swedish Orphan Biovitrum AB
-- Soligenix Inc.
-- Enzychem Lifesciences Corporation
-- Otsuka Pharmaceutical
-- EpicentRx
-- Oragenics Inc
-- Galera Therapeutics
-- Indena S.p.A
-- Innovation Pharmaceuticals
-- Monar Therapeutics
-- Spectrum Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c9nt6w/global_oral?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
